Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 4/20 | 0.34 |
| ▸ | MC5R | P33032 | 4/20 | 0.34 |
| ▸ | MC3R | P41968 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 4/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868126 | 0.88 | KDM1A (0.35) | KDM1AUSP2SIGMAR1PKM | |
| SCHEMBL403197 | 0.77 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL4868613 | 0.75 | SIGMAR1 (0.31) | USP2SIGMAR1 | |
| SCHEMBL404815 | 0.71 | CA12 (0.41) | CA12CA9 | |
| SCHEMBL4871658 | 0.70 | ACKR3 (0.47) | KDM1APKM | |
| SCHEMBL2157188 | 0.63 | CYP3A4 (0.36) | KDM1ASIGMAR1 | |
| SCHEMBL403859 | 0.63 | CSK (0.34) | — | |
| SCHEMBL4868131 | 0.63 | MEN1 (0.33) | KDM1APKM | |
| SCHEMBL5650448 | 0.63 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL24632311 | 0.63 | GRM5 (0.62) | KDM1APBKPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | KDM1A 4512/4885PBK 2047/4885MC4R 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.